ClinicalTrials.gg
CompletedNCT06729073AMZ001Updated Jan 6, 2026Results posted

Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days.

A Phase 1 interventional study of Diclofenac sodium gel and Diclofenac diethylamine 1.16% gel in Healthy Volunteer, sponsored by Amzell. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Amzell · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of the present study is to investigate the systemic bioavailability of AMZ001, applied once daily on each knee compared to Diclofenac diethylammonium gel 1.16%, applied 4 times daily on each knee, after repeated dosing in healthy subjects for 7 days The safety and local tolerability of AMZ001, applied once daily, will be evaluated after repeated dosing in healthy subjects for 7 days

Read the detailed description

On their both knees, participants will apply once daily AMZ001 for 7 consecutive days. Participants will also apply Diclofenac Diethylammonium 1.16% Gel as per label information on each knee.

Intensive pharmacokinetic assessment (blood samplings) will be performed on the first day of application (Day 1) as well as on the last day of application (Day 7).

Each participant will receive each of the two treatments in a randomized manner. Between each treatment, participant will not receive any of tested therapies during at least 21 days before receiving the next therapy. (washout period)

Participants will stay on the clinical unit only during each period of treatment but not during washout period.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • pharmacokinetics
03

In context

Lead sponsor

Amzell is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) within the range of 18.0-30.0 kg/m\^2 (inclusive) at screening
  • Female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    • Is a WONCBP. A must have a negative highly sensitive serum pregnancy test at screening OR
    • Is a WOCBP and using a method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, without interruption, during trial participation and until 30 days after the last administration of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.
  • Participant is overtly healthy as determined by medical evaluation including medical history, full physical examination, vital signs, and
  • Participant is free of any systemic or dermatologic disorder and chronic or acute infections, which, in the opinion of the Investigator, may interfere with the study results or increase the risk of adverse events.
  • Participant is a non-smoker, former smoker or stable non-smoker (= 0 cigarettes, pipes, cigars, or others) for at least 3 months prior to screening. Participant must also have abstained from use of other nicotine containing products (e.g., nicotine patch, chewing gum or e-cigarettes) for at least 3 months before screening.
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in this protocol prior to any clinical study specific procedure.

Exclusion criteria

Exclusion Criteria:

  • Any visible skin disease, skin lesions, wounds, or a significant amount of hair at the application sites (both knees).
  • Any history or evidence of any cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinologic, hematologic, immunologic, metabolic, genitourinary, pulmonary, neurologic, dermatologic, musculoskeletal, psychiatric and/or other major disease as determined by medical evaluation (including [abbreviated] physical examination) capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Any known or suspected , excluding basal cell cancer unless it is associated with the treatment area.
  • Any gastrointestinal bleeding issues, e.g., Gastroesophageal Reflux Disease, Peptic Ulcer Disease.
  • Any hospital admission or major surgery within 30 days prior to randomization
  • History or current evidence of ongoing hepatic disease or impaired hepatic function at screening as indicated by diagnostic assessments
  • History or current evidence of renal disease or impaired renal function at screening as indicated by diagnostic assessments
  • Any clinically relevant history of allergic conditions requiring hospitalization or prolonged systemic treatment (including drug allergies, drug , asthma, angioedema, urticaria, eczema, acute rhinitis precipitated by acetylsalicylic acid or other NSAIDs, allergies requiring therapy with or anaphylactic reactions), excluding allergic contact sensitizations (e.g., nickel allergy). Subjects with uncomplicated seasonal allergic rhinitis can be accepted only if the expected allergy season is clearly outside enrolment/ treatment periods.
  • Known or suspected hypersensitivity to diclofenac, or any components of the formulations used
  • for the use of study interventions
  • Any clinically relevant chronic or acute infectious illnesses or febrile infections within 2 weeks prior to the first scheduled administration of study intervention
  • Evidence of COVID-19 signs or symptoms or confirmed COVID-19 infection within the last 2 weeks prior to screening.
  • Treatment with systemic or local diclofenac within 30 days of enrollment or during the study (except for study interventions).
  • Use of any concomitant medication or any drugs / medicines (including over-the-counter medication, dietary supplements, natural and herbal remedies) within 2 weeks before the first scheduled administration of study intervention or within less than 10 times the elimination half-life of the respective drug (whichever is longer) or is anticipated to require concomitant medication during the 2-week period or at any time throughout the study.
  • Use of any topical medication, cosmetics, cream, ointments, lotions on the treatment site 2 weeks prior to enrollment through EOT visit.
  • Use of any drug or participation in any clinical study within 30 days or 10 half-life times (if known) of study drug administered in a previous trial, whichever is longer, prior to the expected date of first administration of study intervention.
  • Positive for surface antigen (HBsAg), virus antibodies (anti-HCV) and anti- antibodies (anti-HIV 1 and 2 and HIV 1-p24 antigen) at screening
  • Positive screen for alcohol, drugs of abuse and cotinine test at screening.
  • Female subject who plans to become pregnant during the clinical study period and for 3 months after final study intervention administration
  • Donation or blood collection of more than 1 unit (approximately 450 mL) of blood (or blood products) or acute loss of blood during the 30 days prior to randomization.
  • Employee of the Sponsor, or Contract Research Organization (CRO) involved in the clinical study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    AMZ001

    AMZ001 applied once daily for 7 consecutive days

    Drug: Diclofenac sodium gel

  • Active comparator
    Diclofenac diethylamine 1.16%

    Reference product applied four-times daily for 7 consecutive days

    Drug: Diclofenac diethylamine 1.16% gel

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve 0-24h

    Area under the curve from time zero to 24 hours

    Time frame: Day 7

Secondary outcomes

  1. Pharmacokinetic Parameter - Cmin

    Minimum plasma drug concentration (Cmin)

    Time frame: Day 7

  2. Pharmacokinetic Parameter - Cavg

    Average plasma concentration (Cavg)

    Time frame: Day 7

  3. Pharmacokinetic Parameter - Tmax

    Time to reach maximum plasma concentration (Tmax)

    Time frame: Day 7

  4. Compare Exposure to Diclofenac

    Area under the curve from time zero to 24 hours and maximum (peak) plasma drug concentration

    Time frame: Day 1

  5. Pharmacokinetic Parameter - Tmax

    Time to reach maximum plasma concentration (Tmax)

    Time frame: Day 1

  6. Pharmacokinetic Parameter - Cavg

    Average plasma concentration

    Time frame: Day 1

  7. Incidence of Application Site Reactions

    Number of subjects having at least one event

    Time frame: Day 1 to Day 7

07

Results

Posted Jan 6, 2026

Participant flow

1
Participant flow — 1
MilestoneAMZ001/Diclofenac Diethylamine 1.16%Diclofenac Diethylamine 1.16%/AMZ001
Started1717
Completed1717
Not completed00
2
Participant flow — 2
MilestoneAMZ001/Diclofenac Diethylamine 1.16%Diclofenac Diethylamine 1.16%/AMZ001
Started1716
Completed1716
Not completed00

Outcome measures

PrimaryArea Under the Curve 0-24h

Area under the curve from time zero to 24 hours

Time frame:
Day 7
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve 0-24h
h*ng/mLAMZ001Diclofenac Diethylamine 1.16%
Area Under the Curve 0-24h281.60 ± 67.1411.35 ± 57.2
SecondaryPharmacokinetic Parameter - Cmin

Minimum plasma drug concentration (Cmin)

Time frame:
Day 7
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter - Cmin
ng/mLAMZ001Diclofenac Diethylamine 1.16%
Pharmacokinetic Parameter - Cmin5.812 ± 73.110.22 ± 50.2
SecondaryPharmacokinetic Parameter - Cavg

Average plasma concentration (Cavg)

Time frame:
Day 7
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter - Cavg
ng/mLAMZ001Diclofenac Diethylamine 1.16%
Pharmacokinetic Parameter - Cavg11.733 ± 67.117.139 ± 57.2
SecondaryPharmacokinetic Parameter - Tmax

Time to reach maximum plasma concentration (Tmax)

Time frame:
Day 7
Reported as:
Median · h
Pharmacokinetic Parameter - Tmax
hAMZ001Diclofenac Diethylamine 1.16%
Pharmacokinetic Parameter - Tmax6 (0 to 20.017)17.9830 (0 to 24)
SecondaryCompare Exposure to Diclofenac

Area under the curve from time zero to 24 hours and maximum (peak) plasma drug concentration

Time frame:
Day 1
Reported as:
Geometric mean · h*ng/mL
Compare Exposure to Diclofenac
h*ng/mLAMZ001Diclofenac Diethylamine 1.16%
Compare Exposure to Diclofenac141.76 ± 101.686.76 ± 116.3
SecondaryPharmacokinetic Parameter - Tmax

Time to reach maximum plasma concentration (Tmax)

Time frame:
Day 1
Reported as:
Median · h
Pharmacokinetic Parameter - Tmax
hAMZ001Diclofenac Diethylamine 1.16%
Pharmacokinetic Parameter - Tmax9.9170 (4.000 to 23.833)23.8330 (8.000 to 23.883)
SecondaryPharmacokinetic Parameter - Cavg

Average plasma concentration

Time frame:
Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter - Cavg
ng/mLAMZ001Diclofenac Diethylamine 1.16%
Pharmacokinetic Parameter - Cavg5.906 ± 101.63.615 ± 116.3
SecondaryIncidence of Application Site Reactions

Number of subjects having at least one event

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Incidence of Application Site Reactions
ParticipantsAMZ001Diclofenac Diethylamine 1.16%
Incidence of Application Site Reactions01

Adverse events

Collected over From enrollment until end of treatment period 2. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AMZ0010/33 (0%)0/33 (0%)5/33 (15.2%)
Diclofenac Diethylamine 1.16%0/34 (0%)0/34 (0%)8/34 (23.5%)
Most frequent other events
Most frequent other events
EventAMZ001Diclofenac Diethylamine 1.16%
NasopharyngitisInfections and infestations2/333/34
HeadacheNervous system disorders1/332/34
Urinary tract infectionInfections and infestations1/330/34
Abdominal pain upperGastrointestinal disorders1/330/34
CoughRespiratory, thoracic and mediastinal disorders1/330/34
RhinitisInfections and infestations0/331/34
Skin abrasionInjury, poisoning and procedural complications0/331/34
DysuriaRenal and urinary disorders0/331/34
ErythemaSkin and subcutaneous tissue disorders0/331/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)AMZ001/Diclofenac Diethylamine 1.16%Diclofenac Diethylamine 1.16%/AMZ001Total
Mean47.2 ± 12.7544.5 ± 9.9445.8 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)AMZ001/Diclofenac Diethylamine 1.16%Diclofenac Diethylamine 1.16%/AMZ001Total
Female11718
Male61016
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AMZ001/Diclofenac Diethylamine 1.16%Diclofenac Diethylamine 1.16%/AMZ001Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White171532
More than one race011
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AMZ001/Diclofenac Diethylamine 1.16%Diclofenac Diethylamine 1.16%/AMZ001Total
Hispanic or Latino171734
Not Hispanic or Latino000
Unknown or Not Reported000
08

Study locations

1 site
  • Nuvisan
    Neu-Ulm, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Jun 2025, 6 months.

Results were first posted in Jan 2026, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 11, 2024
StartActual
Nov 29, 2024
Primary completionActual
Jun 10, 2025
CompletionActual
Jul 15, 2025
Results first posted
Jan 6, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06729073
Lead sponsor
Amzell
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Nov 29, 2024
Primary completion
Jun 10, 2025
Completion
Jul 15, 2025
Results posted
Jan 6, 2026
Last update
Jan 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion